TCEAL1 and prostate carcinoma: Treatment of the TCEAL1 knocked-out prostate cancer cell line with docetaxel results powerfully in a changed cell cycle profile concomitant with promoted subG1 cell death and also polyploidy (Rushworth et al., 2020).